Ann: Imugene Advances to Phase 2 in Gastric Cancer Trial, page-54

I thought OSU data is out end of next year (Dec 2019), not this year?

I think you’re asking too much for Ph1b, efficacy won’t be discussed much, that’s for Ph2. It will probably be mentioned briefly, who knows. But yesterday’s Ann said TopLine Data, so there could be legal implication for anything less than good results.

If you compare the trading volume at the beginning of the year when the SP shot up from 1.3c to 4c compared to current volume, it shows how cautious & less enthusiastic the market is. Strange really, after all the de-risking announcements. Maybe a worldwide recognition from ESMO will do, but that’s expecting a bit much I guess.

Anyway I’m happy with the scientific progress so far, Kee up the good work Imugene team. Personally yesterday’s Ann gave me a great relief.. now if only the SP goes up back to pre-CR, it might repair a bit of relationship damage with family & friends for recommending Imugene when the SP was around 3c, LOL at least they were forewarned this is a speccy.